After recently writing about Singularity in this column, I felt it was time to address the elephant in the room – the difference between Artificial Intelligence and Human Consciousness in the Age of ...
FY25 margin recovery and stronger balance sheet fuel 6–7% margin target by 2028/29. Read the latest analysis on the stock ...
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipat ...
Thank you. This is one of the largest unmet needs in all of medicine, and we at ClearPoint Neuro, Inc. believe we can play a crucial role in this exciting future. This foundation is made up of four ...
By now, everyone should have access to our Fourth Quarter 2025 earnings, which can be found at elpolloloco.com in the Investor Relations section. Before we begin our formal remarks, I need to remind ...
Solid traffic performance supported by record highs in Argentina, Armenia, Italy and Uruguay Achieved double-digit YoY growth in Adjusted EBITDA ex-IFRIC with margin expanding 4.6pp, ex-one-off impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results